Scholar Rock (SRRK) Expected to Announce Quarterly Earnings on Thursday

Scholar Rock (NASDAQ:SRRK) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $36.35 on Wednesday. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of -15.47 and a beta of 0.50. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The stock’s 50-day moving average is $41.55 and its 200 day moving average is $29.05.

Insider Transactions at Scholar Rock

In other news, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the sale, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This trade represents a 38.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jing L. Marantz sold 5,655 shares of Scholar Rock stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total value of $249,951.00. Following the completion of the sale, the insider now owns 67,200 shares in the company, valued at approximately $2,970,240. This represents a 7.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 149,974 shares of company stock worth $5,927,710. 19.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SRRK shares. Wedbush restated an “outperform” rating and set a $47.00 price target on shares of Scholar Rock in a research report on Wednesday, January 29th. Truist Financial raised their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Finally, HC Wainwright raised their price target on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.